239 related articles for article (PubMed ID: 17239527)
1. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
Culine S
Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527
[No Abstract] [Full Text] [Related]
2. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
Mertens LS; Meijer RP; Kerst JM; Bergman AM; van Tinteren H; van Rhijn BW; Horenblas S
J Urol; 2012 Oct; 188(4):1108-13. PubMed ID: 22901581
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):375-7. PubMed ID: 3301367
[TBL] [Abstract][Full Text] [Related]
5. Response of nude mouse-grown human urothelial cancer to cis-diamminedichloroplatinum(II), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride.
Kyriazis AP; Yagoda A; Kyriazis AA; Fogh J
Cancer Res; 1985 May; 45(5):2012-5. PubMed ID: 3886128
[TBL] [Abstract][Full Text] [Related]
6. Palliative chemoirradiation for transitional carcinoma of the bladder: a case report.
Greenland JD; Bauman GS; Winquist E; Shepherd RR
Can J Urol; 2000 Aug; 7(4):1085-7. PubMed ID: 11109080
[TBL] [Abstract][Full Text] [Related]
7. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of bladder cancer.
Salem PA
Prog Clin Biol Res; 1984; 162B():95-105. PubMed ID: 6209726
[No Abstract] [Full Text] [Related]
9. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
10. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
De Santis M; Bachner M
Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
13. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?
Sonpavde G; Galsky MD; Vogelzang NJ
J Clin Oncol; 2010 Sep; 28(25):e441-2; author reply e443-4. PubMed ID: 20644092
[No Abstract] [Full Text] [Related]
14. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
[TBL] [Abstract][Full Text] [Related]
16. Mobile thrombus in the ascending aorta following cisplatin-based chemotherapy.
Moorjani N; Rubens M; Price S; DeSouza A
J Card Surg; 2013 Jan; 28(1):48-9. PubMed ID: 23199294
[No Abstract] [Full Text] [Related]
17. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Pollera CF; Nelli F
Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
[TBL] [Abstract][Full Text] [Related]
18. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
19. Treatment of invasive bladder cancer (lymph node negative, metastases negative).
Chisholm GD
Prog Clin Biol Res; 1989; 303():559-61. PubMed ID: 2780661
[No Abstract] [Full Text] [Related]
20. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
Rassy E; Assi T; Kattan J
Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
